JP2006516278A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516278A5
JP2006516278A5 JP2006500733A JP2006500733A JP2006516278A5 JP 2006516278 A5 JP2006516278 A5 JP 2006516278A5 JP 2006500733 A JP2006500733 A JP 2006500733A JP 2006500733 A JP2006500733 A JP 2006500733A JP 2006516278 A5 JP2006516278 A5 JP 2006516278A5
Authority
JP
Japan
Prior art keywords
sphingolipid
phytosphingosine
food
lysosphingomyelin
sphinganine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006500733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516278A (ja
Filing date
Publication date
Priority claimed from NL1022443A external-priority patent/NL1022443C2/nl
Application filed filed Critical
Publication of JP2006516278A publication Critical patent/JP2006516278A/ja
Publication of JP2006516278A5 publication Critical patent/JP2006516278A5/ja
Pending legal-status Critical Current

Links

JP2006500733A 2003-01-20 2004-01-20 腸内細菌叢の組成の改善のためのスフィンゴ脂質 Pending JP2006516278A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1022443A NL1022443C2 (nl) 2003-01-20 2003-01-20 Sphingolipiden voor verbetering van de samenstelling van de darmflora.
PCT/NL2004/000046 WO2004064819A1 (en) 2003-01-20 2004-01-20 Sphingolipids for improvement of the composition of the intestinal flora

Publications (2)

Publication Number Publication Date
JP2006516278A JP2006516278A (ja) 2006-06-29
JP2006516278A5 true JP2006516278A5 (https=) 2007-03-01

Family

ID=32768715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006500733A Pending JP2006516278A (ja) 2003-01-20 2004-01-20 腸内細菌叢の組成の改善のためのスフィンゴ脂質

Country Status (7)

Country Link
US (1) US8703172B2 (https=)
EP (1) EP1585509B1 (https=)
JP (1) JP2006516278A (https=)
AT (1) ATE409030T1 (https=)
DE (1) DE602004016727D1 (https=)
NL (1) NL1022443C2 (https=)
WO (1) WO2004064819A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
EP1585508B1 (en) 2003-01-20 2009-04-01 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
JP2005281257A (ja) * 2004-03-30 2005-10-13 Snow Brand Milk Prod Co Ltd 美肌剤
US7906488B2 (en) 2004-11-30 2011-03-15 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae
US8025552B2 (en) * 2004-12-30 2011-09-27 The United States Of America As Represented By The Secretary Of Agriculture Artificial diets for honey bees
GB0513431D0 (en) * 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
US20090162482A1 (en) * 2007-12-21 2009-06-25 S.A.F.E. Research & Development, Llc Nutritional Compositions for Bees
AR077520A1 (es) * 2007-12-21 2011-09-07 Nutricia Nv Uso de esfingomielina y carbohidratos no digeribles para mejorar la microbiota intestinal
JP6675752B2 (ja) * 2016-02-23 2020-04-01 国立大学法人佐賀大学 腸内Blautia coccoides増殖刺激剤

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622666A (en) * 1968-03-04 1971-11-23 Stanley Drug Products Inc Methods for treating bacterial infections with phrenosin
FR2492259A1 (fr) 1980-10-21 1982-04-23 Idinvex Sa Formulation d'heparine
JPS61152632A (ja) 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
JPS6344842A (ja) 1986-08-12 1988-02-25 Kao Corp 油中水中油型乳化油脂組成物
IT1235162B (it) 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisosfingolipidi
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
BR9106744A (pt) 1990-08-13 1993-07-20 Univ Duke Processo para induzir diferenciacao celular,preparacao farmaceutica,composicao e uso de um composto
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5232837A (en) 1991-08-05 1993-08-03 Emory University Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5374616A (en) 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
JPH05320048A (ja) 1992-05-19 1993-12-03 Shiseido Co Ltd 抗酸化剤
US6190894B1 (en) 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6773719B2 (en) 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US20020182250A1 (en) 1995-09-06 2002-12-05 Goro Hori Lipid metabolism improving agent
DE69607854T2 (de) 1995-09-29 2000-08-17 Georgetown University, Washington Sphingosylphosphorylcholin als wirkstoff zur wundheilung
DE19602108A1 (de) 1996-01-22 1997-07-24 Beiersdorf Ag Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
EP0888458A4 (en) 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER
WO1997036996A2 (en) * 1996-03-28 1997-10-09 Gist-Brocades B.V. Process for the preparation of a granular microbial biomass and isolation of valuable compounds therefrom
JP3495740B2 (ja) 1997-04-10 2004-02-09 麒麟麦酒株式会社 α−グリコシルセラミドを含有するNKT細胞活性化剤
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
BR9804872A (pt) 1997-05-02 1999-08-24 Gist Brocades Bv Composi-{es antimicrobianas para uso tÄpico
US5989803A (en) 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
ATE332888T1 (de) * 1997-09-11 2006-08-15 Takara Bio Inc Sphingosinderivate und medizinische zubereitung
DE69943314D1 (de) 1998-02-12 2011-05-12 Kapil N Bhalla Sphingolipid-derivate und verfahren zu deren verwendung
JP3581010B2 (ja) 1998-03-18 2004-10-27 雪印乳業株式会社 脂質の消化吸収機能改善剤
CA2329124A1 (en) 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
AU776785B2 (en) 1999-02-24 2004-09-23 Johns Hopkins University, The Compositions and methods for modulating serum cholesterol
JP3544493B2 (ja) 1999-06-10 2004-07-21 雪印乳業株式会社 乳幼児用栄養組成物
KR100341793B1 (ko) 1999-07-02 2002-06-24 권 영 근 스핑고신 1-포스페이트를 유효성분으로 포함하는 혈관신생 촉진제
WO2001003739A1 (fr) 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
JP2001213858A (ja) 1999-11-24 2001-08-07 Sagami Chem Res Center スフィンゴシン誘導体
JP2001158736A (ja) 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 骨関節疾患の予防及び改善剤
JP2001158735A (ja) 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 歯周病の予防及び改善剤
JP2003523336A (ja) 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
AU2001255199A1 (en) 2000-03-28 2001-10-08 The Liposome Company, Inc. Ceramide derivatives and method of use
JP2002068998A (ja) 2000-08-29 2002-03-08 Meiji Milk Prod Co Ltd 経腸栄養および静脈栄養に伴う脂肪肝発生予防組成物
WO2002034062A1 (en) 2000-10-27 2002-05-02 Nv Marc Boone Method for obtaining products enriched in phospho- and sphingolipids
US6949247B2 (en) 2000-12-28 2005-09-27 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stable skin care compositions containing a retinoid and a retinoid booster system
FR2820037B1 (fr) * 2001-01-29 2005-12-09 Dermaconcept Jmc Composition dermatologique a usage veterinaire comprenant une base sphingoide
JP2002226394A (ja) 2001-02-01 2002-08-14 Meiji Milk Prod Co Ltd 脂質代謝改善組成物
CN102319266B (zh) 2001-06-18 2014-12-17 海王星技术&生物资源有限公司 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
DK1417211T3 (da) 2001-07-27 2007-10-08 Neptune Technologies & Bioress Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse
EP1291340B1 (en) 2001-09-05 2006-03-15 Charmzone Co., Ltd Phytosphingosine derivatives with antitumor activity
US20030109044A1 (en) 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
JP2003155231A (ja) * 2001-11-20 2003-05-27 Kikkoman Corp 医薬及び抗アレルギー剤
JP2003252765A (ja) 2002-02-28 2003-09-10 Snow Brand Milk Prod Co Ltd 腸管運動機能不全性疾患の治療剤
DE10217555A1 (de) 2002-04-19 2004-02-19 Degussa Bioactives Deutschland Gmbh Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
JP2006507223A (ja) 2002-05-17 2006-03-02 エスペリオン セラピューティクス,インコーポレイテッド 脂質代謝異常疾患の治療方法
JP2005535717A (ja) 2002-08-14 2005-11-24 キム,テユン フィトスフィンゴシン誘導体を含むアポトーシス誘導用組成物
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
EP1585508B1 (en) 2003-01-20 2009-04-01 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
GB0301395D0 (en) 2003-01-21 2003-02-19 Univ Aston Inflammatory disorder treatment
US20040171522A1 (en) 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
US9717754B2 (en) 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
AU2004233873B2 (en) 2003-04-25 2010-11-18 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
US8282773B2 (en) 2007-12-14 2012-10-09 Andritz Inc. Method and system to enhance fiber development by addition of treatment agent during mechanical pulping

Similar Documents

Publication Publication Date Title
JP2006516278A5 (https=)
JP2009541393A5 (https=)
US20100298379A1 (en) Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
BG65996B1 (bg) Състав, съдържащ трамадолово производно и антиконвулсантно лекарствено средство
EP2604290A3 (en) Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
IL195732A (en) Pharmaceutical compounds containing passoterodine, their use and method for their preparation
JP2011093933A5 (https=)
Tucker et al. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine
JP2006516280A5 (https=)
JP2014511374A5 (https=)
JP2014141526A5 (https=)
JP2008247856A (ja) Ampk活性化剤
FI4349369T3 (fi) Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa
JP2006516280A (ja) 血漿コレステロール及びトリアシルグリセロールレベルを減少するためにスフィンゴ脂質を使用する方法
JP2001031566A (ja) ペットの問題行動抑制組成物
JP2018537987A5 (https=)
DE602004016727D1 (de) Sphingolipiden zur verbesserung der darmflorazusammensetzung
JP2019515033A5 (https=)
JP2012097036A5 (https=)
BR112014000917A2 (pt) composições
EP3366288B1 (en) Lithium ascorbate exhibiting anti-stress, anxiolytic and anti-depression activity
JP2006517408A5 (https=)
JP2012097034A5 (https=)
US7906488B2 (en) Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae
WO2007021735A2 (en) Use of phospholipid arachidonic acids for increasing muscle mass in humans